# BRE-08 Phase II Study of CMC Regimen for Early Stage Breast Cancer

> **NCT06085742** · PHASE2 · RECRUITING · sponsor: **University of Illinois at Chicago** · enrollment: 25 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** Methotrexate
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT06085742
- **Lead sponsor:** University of Illinois at Chicago
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-11-22
- **Primary completion:** 2034-09
- **Final completion:** 2034-09
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2025-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06085742

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06085742, "BRE-08 Phase II Study of CMC Regimen for Early Stage Breast Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06085742. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*